Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 5 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.

Dementia incidence dropping while overall prevalence continues to climb

18 Dec 2019

While dementia incidence may be declining over time, its overall prevalence keeps on rising, reports a recent Denmark study.

Accessing the National Patient Registry and the Danish Psychiatric Central Research Register, researchers evaluated the longitudinal trends in dementia status in a population of almost 2 million adults aged 65 years. Data analysis was performed between the years 1996 and 2015.

Overall, 152,761 individuals were diagnosed with dementia over 16,944,630 person-years of observation. A total of 170,478 patients had been living with dementia during the 20-year study period. In the same time span, the elderly population jumped from 803,334 in 1996 to 1,055,984 in 2015, but the median age dropped from 74.2 to 72.9 years.

Incidence rates of dementia were significantly higher in 2015 than in 1996. However, this was driven mostly by a steep growth in the number of cases between 1996 to 2003, followed by an unstable plateau until 2010. In the years approaching 2015, dementia incidence dropped moderately.

Adjusting for age and sex, dementia incidence increased by an annual average of 9 percent from 1996 to 2003 and dropped by a yearly mean of 2 percent from 2004 to 2015.

This trend in incidence was accompanied by a steady increase in overall dementia prevalence, regardless of sex and age group. The number of patients with dementia grew from 14,019 in 1996 to 36,129 in 2015, with the rate of increase slowing down in the most recent years.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 5 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.